Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer
Sponsor: Chugai Pharmaceutical
This observational or N/A phase trial investigates Extensive Disease Small Cell Lung Cancer and Non-small Cell Lung Cancer and is currently completed. Chugai Pharmaceutical leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2024 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Sep 2023 — May 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Sep 2021 — Sep 2023 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Dec 2020 [monthly]
Not Yet Recruiting
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chugai Pharmaceutical
- Japan Lung Cancer Society
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akashi, Japan , Amagasaki, Japan , Asahikawa, Japan , Bunkyō City, Japan , Chiba, Japan , Chūōku, Japan , Fujisawa, Japan , Fukui, Japan , Fukuoka, Japan , Fukushima, Japan and 88 more locations